Identifying delirium in people with Parkinson’s disease: the Determine-PD pilot study
Objective: To identify the prevalence of delirium in inpatients with Parkinson’s disease (PD). Background: People with PD may be at increased risk of delirium and…Comparison of Dementia Patients With and Without Parkinson’s Disease Before Dementia-related Psychosis Occurs: An Administrative Claims Data Analysis
Objective: Describe and compare patients with evidence of dementia-related psychosis diagnosed with Parkinson’s disease with dementia (PDD) versus patients with dementia but no Parkinson’s disease…Subacute Encephalopathy with Pimavanserin Treatment in Parkinson Disease
Objective: To report 3 cases of drug-induced encephalopathy in patients treated with pimavanserin (PVN) for Parkinson disease (PD) related psychosis (PDP). Background: Quetiapine and clozapine,…Electroconvulsive Therapy (ECT): An Effective Option for the Treatment of Medication-Resistant Psychiatric Symptoms in Huntington’s Disease: A Case Series and Review of the Literature
Objective: Through a single site case series, we investigate the use and effectiveness of electroconvulsive therapy (ECT) for the treatment of refractory psychiatric symptoms in…Visual subnetwork dysfunction in Parkinson’s patients with primary visual hallucinations
Objective: To evaluate impairments in the visual subnetwork in Parkinson’s disease (PD) patients with psychosis using BOLD fMRI Background: Psychosis occurs in 20-70% of patients…Use of Inappropriate Antipsychotics Among US Long-Term Care Residents with Parkinson’s Disease Psychosis
Objective: To characterize the use of inappropriate antipsychotic therapies among residents with Parkinson’s disease psychosis (PDP) in long-term care (LTC) settings in the US. Background:…Evaluating the Inappropriate Use of Antipsychotics in Parkinson’s Disease Psychosis Patients Within Large National US Healthcare Databases
Objective: To identify Parkinson’s disease psychosis (PDP) treatment characteristics from an aggregate of US national insurer and Medicare databases. Background: Treatment of psychotic symptoms associated…A life-threatening case of Anti-IgLON5 disease
Objective: To present a case of anti-IgLON5 disease with life-threatening respiratory complications. Background: Anti-IgLON5 disease is a little known CNS disorder characterized by non-REM and…The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: We seek to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…LY-341,495, an mGlu2/3 antagonist, abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2/3 orthosteric agonist LY-354,740 in the MPTP-lesioned marmoset
Objective: We aim to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 13
- Next Page »